WGS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

GeneDx Holdings Corp. · Healthcare · Diagnostics & Research

Open interactive chart View report data
Latest close 65.11 USD
10.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -8.7% below the Trend Line and sits at 23.7% of its 52-week range. The latest completed week returned 10.2%, after a -3.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. Options positioning is mixed with 32/100 conviction, while the latest news-sentiment score is 32/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 35 out of 100
Latest Close 65.11 USD 31 Jul 2026
1W Return 10.2% latest completed week
4W Return -3.6% short-term follow-through
12W Return 59.7% quarterly tape
Trend Breadth 44.2% 23 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 10.2% Latest completed week; four-week move -3.6%. Indicator stack 24/63 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 32/100 conviction; expected move 19.0%. News sentiment 32/100 42 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -8.7% below the Trend Line and sits at 23.7% of its 52-week range. The latest completed week returned 10.2%, after a -3.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1512-week average 0.06

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.15Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -3.6% over four weeks, 59.7% over 12 weeks, and -35.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W10.2%
4W-3.6%
12W59.7%
26W-32.4%
52W-35.9%
Active trend streak0 weeks
Active weeks in one year23
Trend breadth44.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.60Latest activity-pressure read.
Pressure change27.8%Four-week change in activity pressure.
Leadership-39.90Latest relative-leadership reading.
RS change4.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength5/100Blend of value, momentum, and quality. Underlying universe rank 96; rank 1 is best.
Value18/100Relative valuation strength. Underlying universe rank 83; rank 1 is best.
Quality24/100Profitability and accounting quality. Underlying universe rank 77; rank 1 is best.
Momentum15/100Medium-term price momentum. Underlying universe rank 86; rank 1 is best.
Growth84/100Revenue and earnings growth. Underlying universe rank 17; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
4.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
0.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
68.3%
Gross profit retained from each unit of revenue.
Operating margin
-16.9%
Operating profit retained from revenue.
Free-cash-flow margin
2.3%
Free cash flow generated from revenue.
Return on invested capital
-17.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
34.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
8.1%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-7.4%
Net share repurchases relative to market value.
Shareholder yield
-7.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

WGS shows mixed options pressure with a 32/100 conviction score, put-call volume ratio of 1.05, expected move of 19.0%, and Sharemaestro trend signal inactive.

Conviction32/100
Expected move19.0%
Put/call volume1.05
Pressure5
Speculation41
Volatility96
Trend agreement45
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment32/100

Weighted news tone is negative across 42 relevant articles.

3 positive · 17 neutral · 22 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
Options expected move19.0%Nearest-chain priced movement where available.
52-week drawdown-61.9%Distance below the 52-week high.
13-week volatility13.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+18.3%Week of 26 Jun.
Worst week-37.6%Week of 8 May.
Latest week+10.2%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains2
Flat weeks0
Modest losses6
Sharp losses9
Recent vol13.9%13-week weekly-return volatility.
Base vol10.5%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew8.0% / -7.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape28/100

Trend, activity pressure, participation, and risk combine to a 28/100 tape read.

 Indicator analysis22/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 0/12.

Activity pressure 0.15; No reversal markers Factors14/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 84; Small Cap Core rank 85 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

WGS shows mixed options pressure with a 32/100 conviction score, put-call volume ratio of 1.05, expected move of 19.0%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 19.0% Sentiment32/100

Weighted news tone is negative across 42 relevant articles.

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS Insiders50/100

No recent insider transaction evidence is stored.

 Earnings2d

Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202665.11 USD10.2%71.28 USD60.17 USD0.60-39.904.1MOff
24 Jul 202659.10 USD-6.9%73.52 USD59.79 USD0.60-45.742.8MOff
17 Jul 202663.48 USD-3.3%76.01 USD59.46 USD0.68-43.033.6MOff
10 Jul 202665.64 USD-2.8%78.58 USD59.10 USD0.58-43.863.2MOff
3 Jul 202667.51 USD-3.3%81.44 USD58.73 USD0.47-41.633.2MOff
26 Jun 202669.82 USD18.3%84.49 USD58.33 USD0.27-39.626.0MOff
19 Jun 202659.01 USD-1.5%87.72 USD57.92 USD-0.00-51.653.6MOff
12 Jun 202659.92 USD14.8%90.64 USD57.58 USD-0.19-49.876.6MOff
5 Jun 202652.21 USD0.4%92.91 USD57.24 USD-0.46-55.526.1MOff
29 May 202651.99 USD9.9%95.83 USD56.95 USD-0.55-58.004.5MOff
22 May 202647.31 USD16.1%98.66 USD56.65 USD-0.65-60.987.7MOff
15 May 202640.75 USD-0.0%101.4 USD56.40 USD-0.71-66.277.5MOff
8 May 202640.77 USD-37.6%104.1 USD56.18 USD-0.85-66.6424.7MOff
1 May 202665.38 USD-4.6%106.8 USD55.96 USD-1.08-43.962.6MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.